The Motley Fool
24 Sept 2026, 04:30 UTC · 1h ago
Verdict
Headline takes no side. We score ABBV −0.20 across four claims — slightly bearish.
−0.20slightly bearish
More negative than 66% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
AbbVie released positive phase 3 trial data on September 3 for its T-cell engager therapy etentamig to treat multiple myeloma.
Priced indata released Sept 3
More positive than 77% of claims this week
AbbVie estimates high single-digit sales growth through the end of the decade.
Priced in
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
So whatMaintaining a ~7-9% growth rate through 2030 requires Skyrizi and Rinvoq to offset the loss of 14 patent-expiring drugs.
More positive than 64% of claims this week
The company increased its dividend by 5.5% this year, marking 53 consecutive years of increases.
Priced inanalysis of annual dividend hike
So whatThe current 5.5% clip is a significant deceleration from the 10-year average of 11.9% to 12% cited.
More positive than 42% of claims this week
AbbVie has 14 drugs facing patent expirations between now and 2031, with only Vraylar currently among its top 10-selling therapies.
Priced inanalysis of patent trends
So whatLimited concentration of top-tier revenue in the expiring pipeline reduces the immediate risk of a massive EPS cliff before 2031.
More positive than 42% of claims this week
Which stocks this story touches
More negative than 66% of ticker scores this week
While acknowledging strong historical returns and R&D progress, the author warns of a high P/E ratio, lower dividend yield, and limited room for further growth.
Near neutral — 92% of ticker scores this week are stronger
Mentioned only as a historical corporate parent to establish dividend history.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
—
ABBV hasn't traded since this ran. Last close $265.30 (Sep 23); the reaction starts at the next open.
ABBV chart →
